Dermal Substitution in Pediatric Burns (GlyPeB)

April 10, 2024 updated by: Radboud University Medical Center

Dermal Substitution in Paediatric Burns: A Prospective Case Series

The standard treatment of deep dermal to full thickness burns is surgical removal of the burn followed by skin transplantation. Dermal substitutes are increasingly used in the treatment of deep burns to replace lost dermis. Preservation of the collagen and elastin in the acellular human dermal substitute Glyaderm provides a more elastic scar. It is unknown what the effect of Glyaderm on scar quality is in a solely paediatric population.

The objective of this case series is to investigate scar maturation and scar quality when applying Glyaderm in deep dermal to full thickness burns in a pediatric population aged ≤15 years old.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

20

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Nijmegen, Netherlands
        • Recruiting
        • Radboudumc
        • Contact:
          • Elleke Munk, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

No older than 15 years (Child)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Age ≤15 years old
  2. Burn wounds requiring skin grafting
  3. Written informed consent provided by

    1. The participant's parent(s)/guardian (<12 years of age)
    2. The participant's parent(s)/guardian and the participant itself (12-15 years old)

Exclusion Criteria:

  1. Burn wound of ≤30 cm2
  2. Infected burn wounds: clinical symptoms in combination with positive wound swabs
  3. Patients/parents with insufficient knowledge of the Dutch or English language, since they would not be able to complete the POSAS questionnaire.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Glyaderm
All included patients will undergo full thickness removal of the burned skin or adequate debridement of all necrotic tissue. Next, the dermal substitute Glyaderm followed by a split thickness skin graft will be transplanted on the wound.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Scar quality (clinician)
Time Frame: 12 months
Scar quality measured using the Patient and Observer Scar Assessment Scale (POSAS) Observer Scale, which rates the scar from 1 (=like normal skin) to 10 (=worst scar imaginable).
12 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Clinical assessment of the graft take
Time Frame: 5-7 days after STSG application
Take of the split thickness skin graft (STSG) in percentages. The take is defined as STSG that appears vital and is adherent to the wound bed.
5-7 days after STSG application
Wound epithelialization
Time Frame: 5-7 days after STSG application
Wound epithelialization is the percentage of the graft with a vital skin graft and healed graft interstices.
5-7 days after STSG application
Wound healing time
Time Frame: determined in the first several days to weeks after STSG application
>95% epithelialization of the wound area is considered as healed
determined in the first several days to weeks after STSG application
Donor site healing time
Time Frame: determined in the first several days to weeks after STSG application
>95% epithelialisation of the donor site wound surface area is considered as healed
determined in the first several days to weeks after STSG application
Scar surface area
Time Frame: day of surgery (day 0) and 3, 6 and 12 months post-surgery
The scar surface area is calculated using the surgery wound as reference area
day of surgery (day 0) and 3, 6 and 12 months post-surgery
Scar quality (participant)
Time Frame: 3, 6 and 12 months post-surgery
Scar quality measured using the Patient and Observer Scar Assessment Scale (POSAS) Patient Scale, rating the scar from 1 (=like normal skin) to 10 (=worst scar imaginable).
3, 6 and 12 months post-surgery
Occurrence of scar contractures
Time Frame: Up to 12 months post-surgery
Scar contractures often occur in children with deep dermal and full thickness burn wounds.
Up to 12 months post-surgery
Occurrence of scar hypertrophy
Time Frame: Up to 12 months post-surgery
Scar hypertrophy often occurs in children with deep dermal and full thickness burn wounds.
Up to 12 months post-surgery
Range of motion of affected joints
Time Frame: 3, 6 and 12 months post-surgery
When joints are affected due to the burn wound, the range of motion of the affected joint(s) will be monitored during follow-up.
3, 6 and 12 months post-surgery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Marielle Vehmeijer-Heeman, MD, PhD, Radboud University Medical Center

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 1, 2022

Primary Completion (Estimated)

November 1, 2025

Study Completion (Estimated)

November 1, 2025

Study Registration Dates

First Submitted

March 15, 2022

First Submitted That Met QC Criteria

March 24, 2022

First Posted (Actual)

April 4, 2022

Study Record Updates

Last Update Posted (Actual)

April 12, 2024

Last Update Submitted That Met QC Criteria

April 10, 2024

Last Verified

November 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2022-13625

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Burn Scar

Clinical Trials on Glyaderm

Subscribe